자궁경부암 환자 혈청에서 인유두종바이러스 16 DNA와 임상병리학적 예후인자들의 관계 = The relationship between serum human papillomavirus 16 DNA and clinicopathological prognostic factors in cervical cancer patients

다국어 초록 (Multilingual Abstract)

Objective: To study the relationship between serum human papillomavirus (HPV) deoxyribonucleic acid (DNA) and clinicopathologic prognostic factors and the clinical usefulness of serum HPV 16 DNA in cervical cancer patients. Methods: All the patients were treated at our institution, from January, 2002 to February, 2007. DNA extracted from serum of 17 patients with HPV 16 infected carcinoma in situ and 65 patients with HPV 16 infected squamous cell carcinoma of the uterine cervix (stage IA-IIIB) were examined for HPV 16 DNA using polymerase chain reaction with types 16 specific E6 primer. Clinicopathological parameters were obtained from medical records, and the relationship between the discrete variables and serum HPV 16 DNA status were evaluated. Results: HPV 16 DNA was not detected in serum from all patients with carcinoma in situ. However, among the 65 patients with HPV 16 infected squamous cell carcinoma of the uterine cervix, we detected 17 HPV 16 DNA positive samples (26.2%) in serum. Positive HPV 16 DNA in serum was correlated with age (P=0.0071), serum squamous cell carcinoma (SCC) antigen (P=0.0034), tumor size (P=0.0029), clinical stage (P<0.0001), deep stromal invasion (P=0.0048), resection margin positivity (P=0.0008), and pelvic lymph nodal metastasis (P=0.0040). Conclusion: The serum HPV 16 DNA in patients with cervical cancer was correlated with poor prognostic factors that need adjuvant treatment.

참고문헌 (Reference)

1 김용범, "한국여성의 자궁경부암에서 인유두종바이러스의 감염 양상" 대한산부인과학회 46 (46): 789-794, 2003

2 대한산부인과학회 부인종양위원회, "한국부인 암등록사업조사보고서 (2002.1.1-2002.12.31)" 47 : 1029-1070, 2004

3 최순호, "자궁경부의 인유두종바이러스 아형의 분석과 HP DNA chip 검사의 임상적 유용성" 대한산부인과학회 50 (50): 465-475, 2007

4 이제훈, "자궁경부의 인유두종 바이러스 검출에 있어 HPV DNA chip 검사의 임상적 유용성" 대한산부인과학회 49 (49): 2128-2136, 2006

5 임수빈, "자궁 경부 세포진 검사 미확정 편평세포에서 HPV DNA chip검사의 유용성" 46 : 2451-2457, 2003

6 Havre PA, "p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells" 55 : 4420-4424, 1995

7 Chao A, "Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization" 190 : 1046-1051, 2004

8 Remmink AJ, "The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months" 61 : 306-311, 1995

9 Stroun M, "The origin and mechanism of circulating DNA" 906 : 161-168, 2000

10 Stroun M, "The origin and mechanism of circulating DNA" 906 : 161-168, 2000

11 Lo YM, "Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma" 59 : 5452-5455, 1999

12 Sevin BU, "Prognostic factors of early stage cervical cancer treated by radical hysterectomy" 76 : 1978-1986, 1995

13 Bosch FX, "Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group" 87 : 796-802, 1995

14 Wells SI, "Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21 (CIP)-dependent pathways" 19 : 5762-5771, 2000

15 Rozendaal L, "PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears" 68 : 766-769, 1996

16 Woodman CB, "Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study" 357 : 1831-1836, 2001

17 Liu VW, "Low incidence of HPV DNA in sera of pretreatment cervical cancer patients" 82 : 269-272, 2001

18 Castells A, "K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance" 17 : 578-584, 1999

19 Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide" 189 : 12-19, 1999

20 Muñoz N, "Human papillomavirus and cancer: the epidemiological evidence" 19 : 1-5, 2000

21 Widschwendter A, "Human papillomavirus DNA in sera of cervical cancer patients as tumor marker" 202 : 231-239, 2003

22 Pornthanakasem W, "Human papillomavirus DNA in plasma of patients with cervical cancer" 1 : 2-, 2001

23 Myers G, "Heterogeneity of papillomaviruses" 7 : 349-358, 1996

24 Mutirangura A, "Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma" 4 : 665-669, 1998

25 Muñoz N, "Epidemioloic classification of human papillomavirus types associated with cervical cancer" 348 : 518-527, 2003

26 Romney SL, "Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection" 65 : 483-492, 1997

27 Fuller AF Jr, "Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix" 33 : 34-39, 1989

28 Pao CC, "Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis" 15 : 1008-1012, 1997

29 Anker P, "Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients" 18 : 65-73, 1999

30 Dong SM, "Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma" 11 : 3-6, 2002

31 Capone RB, "Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associate wiead and neck squamous cell carcinoma" 6 : 4171-4175, 2000

32 Hsu KF, "Clinical significance of serum human papillomavirus DNA in cervical carcinoma" 102 : 1344-1351, 2003

33 De Villiers EM, "Classification of papillomaviruses" 324 : 17-27, 2004

34 Sidransky D, "Circulating DNA: what we know and what we need to learn" 906 : 1-4, 2000

35 "Cancer incidence in five continents. Volume Ⅷ. 155" IARC Sci Publ 1-781, 2002

36 Chan SY, "Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy" 69 : 3074-3083, 1995

37 Jen J, "An overview on the isolation and analysis of circulating tumor DNA in plasma and serum" 906 : 8-12, 2000

38 Castle PE, "Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive, cytologically negative women" 95 : 2145-2151, 2002